Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside
- PMID: 29201312
- PMCID: PMC5686300
- DOI: 10.22088/cjim.8.4.228
Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside
Abstract
Immunotherapy has been used for years in many types of cancer therapy. Recently, cancer immunotherapy has focused on mechanisms which can enhance the development of cell-mediated immunity. Anticancer medications are administered to inhibit immunosuppressive factors such as nagalase enzyme, which is produced by neoplastic cells and destroys macrophage activating factor (Gc-MAF). Anti-neoplastics medications can also enhance immune-cell activity against tumors. Such medications show great potential in cancer immunotherapy using natural human mechanisms against neoplasms.
Keywords: Cancer; Gc-MAF; Immunotherapy; Macrophage activating factor; Vitamin D..
Conflict of interest statement
There is no conflict of interest.
Figures
References
-
- Cheon S, Agarwal A, Popovic M, et al. The accuracy of clinicians' predictions of survival in advanced cancer: a review. Ann Palliat Med. 2016;5:22–9. - PubMed
-
- Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect? Biochem Pharmacol. 2016;102:1–6. - PubMed
-
- Ortiz R, Melguizo C, Prados J, et al. New gene therapy strategies for cancer treatment: a review of recent patents. Recent Pat Anticancer Drug Discov. 2012;7:297–312. - PubMed
-
- Pergialiotis V, Pitsouni E, Prodromidou A, et al. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause. 2016;23:335–42. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous